LMO7

Across TCGA pan-cancer cohorts, LMO7 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LMO7 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LMO7 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LMO7 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and COAD show a favorable association.

CCRCC, COAD, and UCEC are the cancer types where LMO7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.862	0.346	<.001	53	view →
COAD	DFS	Median	II,III,IV	1.000	0.884	.025	48	view →
UCEC	DFS	Quartile	All	1.000	0.843	.019	36	view →
HNSC	OS	Median	IV	0.832	0.617	.015	5	view →
LSCC	OS	Quartile	All	0.952	1.000	.031	4	view →
PDAC	DFS	Tertile	IV	0.217	0.777	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LMO7–CCRCC (DFS)

Open the CCRCC breakdown →